SCHEMBL1688321

SCHEMBL1688321

CCNC(=O)CCCS(=O)(=O)NC(=O)CCCCCCCCCCCCCCCc1nnn[nH]1

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.38
ITGB3 P05106 1/20 0.32
ITGAV P06756 1/20 0.32
PPARG P37231 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16093430 0.95 FAAH (0.34) FAAHPPARG
SCHEMBL12809270 0.91 FAAH (0.34) FAAHPPARG
SCHEMBL13892164 0.90 FAAH (0.38) FAAH
SCHEMBL13226753 0.90 ALDH1A1 (0.32) FAAHPPARG
SCHEMBL12673964 0.90 PPARG (0.36) FAAHITGB3ITGAVPPARG
SCHEMBL1688196 0.90 PPARG (0.36) FAAHITGB3ITGAVPPARG
SCHEMBL16093010 0.89 CASP2 (0.40) FAAH
SCHEMBL13113625 0.89 CASP2 (0.40) FAAH
SCHEMBL12641022 0.88 PPARG (0.30) PPARG
SCHEMBL13694066 0.88 PPARG (0.30) PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067977-B2 Peptides derivatized with A-B-C-D- and their therapeutical use NOVO NORDISK A/S (DK) 2015-06-30 US disclosed
US-9061067-B2 Polypeptide protracting tags NOVO NORDISK A/S (DK) 2015-06-23 US disclosed
US-8841249-B2 Growth hormones with prolonged in-vivo efficacy NOVO NORDISK A/S (DK) 2014-09-23 US disclosed
US-20140011732-A1 Peptides Derivatized with A-B-C-D- and their Therapeutical Use NOVO NORDISK A/S (DK) 2014-01-09 US disclosed
US-20120088716-A1 Polypeptide Protracting Tags NOVO NORDISK A/S (DK) 2012-04-12 US disclosed
US-20090111730-A1 Polypeptide protracting tags NOVO NORDISK A/S (DK) 2009-04-30 US disclosed
US-20090111730-A1 Polypeptide protracting tags NOVO NORDISK A/S (DK) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011732-A1 Peptides Derivatized with A-B-C-D- and their Therapeutical Use GLP1R, IAPP, GIPR FAAH 1208/4885ITGB3 2129/4885ITGAV 2588/4885
US-20120088716-A1 Polypeptide Protracting Tags VIP, FGB, NPPA FAAH 2944/4885ITGB3 672/4885ITGAV 407/4885
US-20090111730-A1 Polypeptide protracting tags LNPEP, FGB, ENPEP FAAH 2903/4885ITGB3 630/4885ITGAV 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.